INFORMATION BY CANCER TYPE

Leukemia

Examining the Safety of CLL Medication
BY Nitin Jain, M.D.
OVER THE LAST FEW years, significant advances were made in the treatment of patients with chronic lymphocytic leukemia (CLL). Several novel therapies, most of them oral, have now been approved by the Food and Drug Administration. These include Imbruvica (ibrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor; Venclexta (venetoclax), a B-cell lymphoma-2 (BCL2) inhibitor; and Zydelig (idelalisib), a phosphoinositide 3-kinase (PI3K) inhibitor.
Drug Provides High Response Rate in CLL
Venclexta (venetoclax), a BCL-2 inhibitor, had promising results in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). According to an updated analysis of a clinical trial, the agent led to negative minimal residual disease (MRD) in 40 percent of patients involved.
 
Treatment Stages for a Rare Leukemia
BY Tara Haelle
THERE ARE THREE STAGES of treatment for acute promyelocytic leukemia: induction therapy, consolidation therapy and maintenance therapy.
Advances Lead to Higher Cure Rate for Rare Leukemia Type
BY Tara Haelle
Treatment advances mean high cure rate for patients with APL.
A Message in a Bone
BY Gary Stromberg
When Gary found out that his daughter was a match to donate bone marrow to a 69-year-old man, he collapsed and cried on the streets of Santa Monica.
Novel Agent Shows Promise in AML Treatment
BY Danielle Bucco
A novel agent is attacking a newly found target in patients with acute myeloid leukemia (AML).
New CAR T-Cell Therapy Comes With a Hefty Price Tag
BY Tony Hagen
The newly approved CAR T-cell therapy, Kymriah (tisagenlecleucel), is being put on the market with a price tag of $475,000 for a single infusion, which is within the range that oncologists predicted.
 
FDA Approves Kymriah for Pediatric and Young Adult ALL
Kymriah, a CAR T-cell therapy, was approved to treat certain pediatric and young adult patients who have acute lymphoblastic leukemia (ALL). 
Bosulif Granted Priority Review in CML
BY Jason Harris
Bosulif (bosutinib) was granted a priority review to a supplemental new drug application (sNDA) by the Food and Drug Administration (FDA) for use in the first-line treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML).
Faces of Cancer: Jack's Journey
BY Kim Johnson
We can all learn some things from an extraordinary young man.
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Leukemia CURE discussion group.
Search Cancer Drugs & Terms
Treatment
Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
Adult Acute Lymphoblastic Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of adult acute lymphoblastic leukemia.
Adult Acute Myeloid Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of adult acute myeloid leukemia.
Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of childhood acute lymphoblastic leukemia.
Chronic Lymphocytic Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia.
Chronic Lymphocytic Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia.
Chronic Myelogenous Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of chronic myelogenous leukemia.
Hairy Cell Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of hairy cell leukemia.
x
//For side ad protocol